Dipeptidyl Peptidase-IV Inhibitors for Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus: A Systematic Review
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions caused by a build-up of fat in the liver, in the absence of alcohol. It is an important public health concern due to the increasing obesity epidemic. Patients with type 2 diabetes mellitus (T2DM) and NAFLD are at a higher risk of developing severe forms of NAFLD. There is growing evidence for the use of incretin-based therapies, such as dipeptidyl-peptidase-IV inhibitors (DPP-IV inhibitors), to treat the condition. The aim of this review was to determine whether DPP-IV inhibitors are effective in improving NAFLD in T2DM patients.
A systematic review was done and the Jadad scoring system was used to assess the methodological quality of trials.
Only 4 trials fit the inclusion criteria resulting in a total of 168 participants. This review provides further evidence that sitagliptin does not significantly improve hepatic fat content or NAFLD progression according to; histological assessment, MRI imaging and serum ALT levels. The results were limited by a low number of RCTs investigating a wide range of DPP-IV inhibitors, inconsistency between trials, low sample numbers, short duration and a lack of reporting diet and exercise regimes.
Future trials are needed to accurately conclude the efficacy of DPP-IV inhibitors on NAFLD in T2DM patients. These trials should be long in duration and have a large ethnically diverse sample size. Standardisation is required in trials, both in the types of participants included and in the method of measuring drug treatment outcomes.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.